Emerging and investigational therapies for neuroblastoma.
Expert Opin Orphan Drugs. 2017;5(4):355-368
Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL
Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.